Specifications
Antibody Isotype
IgG1, kappa
Applications
Application Notes
ELISA, FACS, FuncS, Reference antibody
Each laboratory should determine an optimum working titer for use in its particular application.
Other applications have not been tested but use in such assays should not necessarily be excluded.
General Notes
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells.
Target
Alternative Names
Vulinacimab; HLX-06; CD309; KDR; VEGFR-2; VEGFR2
Custom Antibody Labeling
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody.
Learn More
Citations
Have you cited DMAB-C3Y25219 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Faibish, M; Francescone, R; et al. A YKL-40-Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers. MOLECULAR CANCER THERAPEUTICS 10:742-751(2011).
Giatromanolaki, A; Koukourakis, MI; et al. Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. CLINICAL & EXPERIMENTAL METASTASIS 18:313-319(2000).
COA
Certificate of Analysis
![Human Anti-Human VEGFR2 (Ramucirumab) Monoclonal Antibody, clone Ramucirumab [Biosimilar] (CABT-Z696H)](https://img2.creative-diagnostics.com/productimage/CABT-Z696H_1.jpg)
